Dyslipidemia - Pipeline Review, H2 2016

Publisher Name :
Date: 31-Aug-2016
No. of pages: 339
Inquire Before Buying

Dyslipidemia - Pipeline Review, H2 2016

Summary

Global Markets Direct's, ‘Dyslipidemia - Pipeline Review, H2 2016', provides an overview of the Dyslipidemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Dyslipidemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dyslipidemia and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Dyslipidemia

- The report reviews pipeline therapeutics for Dyslipidemia by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Dyslipidemia therapeutics and enlists all their major and minor projects

- The report assesses Dyslipidemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Dyslipidemia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Dyslipidemia

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Dyslipidemia pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Dyslipidemia - Pipeline Review, H2 2016

Table of Contents
Table of Contents 2
Introduction 6
Dyslipidemia Overview 7
Therapeutics Development 8
Dyslipidemia - Therapeutics under Development by Companies 10
Dyslipidemia - Therapeutics under Investigation by Universities/Institutes 15
Dyslipidemia - Pipeline Products Glance 16
Dyslipidemia - Products under Development by Companies 20
Dyslipidemia - Products under Investigation by Universities/Institutes 28
Dyslipidemia - Companies Involved in Therapeutics Development 29
Dyslipidemia - Therapeutics Assessment 90
Drug Profiles 107
Dyslipidemia - Dormant Projects 289
Dyslipidemia - Discontinued Products 306
Dyslipidemia - Product Development Milestones 312
Appendix 324

List of Tables
Number of Products under Development for Dyslipidemia, H2 2016 22
Number of Products under Development for Dyslipidemia - Comparative Analysis, H2 2016 23
Number of Products under Development by Companies, H2 2016 25
Number of Products under Development by Companies, H2 2016 (Contd..1) 26
Number of Products under Development by Companies, H2 2016 (Contd..2) 27
Number of Products under Development by Companies, H2 2016 (Contd..3) 28
Number of Products under Investigation by Universities/Institutes, H2 2016 29
Comparative Analysis by Late Stage Development, H2 2016 30
Comparative Analysis by Clinical Stage Development, H2 2016 31
Comparative Analysis by Early Stage Development, H2 2016 32
Comparative Analysis by Unknown Stage Development, H2 2016 33
Products under Development by Companies, H2 2016 34
Products under Development by Companies, H2 2016 (Contd..1) 35
Products under Development by Companies, H2 2016 (Contd..2) 36
Products under Development by Companies, H2 2016 (Contd..3) 37
Products under Development by Companies, H2 2016 (Contd..4) 38
Products under Development by Companies, H2 2016 (Contd..5) 39
Products under Development by Companies, H2 2016 (Contd..6) 40
Products under Development by Companies, H2 2016 (Contd..7) 41
Products under Investigation by Universities/Institutes, H2 2016 42
Dyslipidemia - Pipeline by Acasti Pharma Inc., H2 2016 43
Dyslipidemia - Pipeline by AFFiRiS AG, H2 2016 44
Dyslipidemia - Pipeline by Akcea Therapeutics Inc, H2 2016 45
Dyslipidemia - Pipeline by Allergan Plc, H2 2016 46
Dyslipidemia - Pipeline by Alnylam Pharmaceuticals, Inc., H2 2016 47
Dyslipidemia - Pipeline by Amgen Inc., H2 2016 48
Dyslipidemia - Pipeline by Arisaph Pharmaceuticals, Inc., H2 2016 49
Dyslipidemia - Pipeline by AstraZeneca Plc, H2 2016 50
Dyslipidemia - Pipeline by BASF SE, H2 2016 51
Dyslipidemia - Pipeline by BCWorld Pharm Co. Ltd., H2 2016 52
Dyslipidemia - Pipeline by BioRestorative Therapies, Inc., H2 2016 53
Dyslipidemia - Pipeline by Cadila Pharmaceuticals Limited, H2 2016 54
Dyslipidemia - Pipeline by Cardax, Inc., H2 2016 55
Dyslipidemia - Pipeline by Catabasis Pharmaceuticals, Inc., H2 2016 56
Dyslipidemia - Pipeline by Cerenis Therapeutics Holding SA, H2 2016 57
Dyslipidemia - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2016 58
Dyslipidemia - Pipeline by CJ HealthCare Corp., H2 2016 59
Dyslipidemia - Pipeline by Connexios Life Sciences Pvt. Ltd., H2 2016 60
Dyslipidemia - Pipeline by CymaBay Therapeutics, Inc., H2 2016 61
Dyslipidemia - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2016 62
Dyslipidemia - Pipeline by Daiichi Sankyo Company, Limited, H2 2016 63
Dyslipidemia - Pipeline by Debiopharm International SA , H2 2016 64
Dyslipidemia - Pipeline by Eli Lilly and Company, H2 2016 65
Dyslipidemia - Pipeline by Esperion Therapeutics, Inc., H2 2016 66
Dyslipidemia - Pipeline by Gemphire Therapeutics Inc., H2 2016 67
Dyslipidemia - Pipeline by GlaxoSmithKline Plc, H2 2016 68
Dyslipidemia - Pipeline by Golden Biotechnology Corp., H2 2016 69
Dyslipidemia - Pipeline by HanAll Biopharma Co., Ltd., H2 2016 70
Dyslipidemia - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2016 71
Dyslipidemia - Pipeline by Huons Co., Ltd., H2 2016 72
Dyslipidemia - Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2016 73
Dyslipidemia - Pipeline by Innovent Biologics, Inc., H2 2016 74
Dyslipidemia - Pipeline by IPCA Laboratories Limited, H2 2016 75
Dyslipidemia - Pipeline by Jeil Pharmaceutical Co., Ltd., H2 2016 76
Dyslipidemia - Pipeline by Jenrin Discovery, Inc., H2 2016 77
Dyslipidemia - Pipeline by JW Pharmaceutical Corporation, H2 2016 78
Dyslipidemia - Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2016 79
Dyslipidemia - Pipeline by Kotobuki Pharmaceutical Co., Ltd., H2 2016 80
Dyslipidemia - Pipeline by Kowa Company, Ltd., H2 2016 81
Dyslipidemia - Pipeline by Kymab Limited, H2 2016 82
Dyslipidemia - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2016 83
Dyslipidemia - Pipeline by LG Life Science LTD., H2 2016 84
Dyslipidemia - Pipeline by Lipicard Technologies Limited, H2 2016 85
Dyslipidemia - Pipeline by Lipigon Pharmaceuticals AB, H2 2016 86
Dyslipidemia - Pipeline by LipimetiX Development Inc, H2 2016 87
Dyslipidemia - Pipeline by Lotus Pharmaceutical Co., Ltd., H2 2016 88
Dyslipidemia - Pipeline by Matinas BioPharma Holdings, Inc. , H2 2016 89
Dyslipidemia - Pipeline by Merck & Co., Inc., H2 2016 90
Dyslipidemia - Pipeline by Nimbus Therapeutics, LLC, H2 2016 91
Dyslipidemia - Pipeline by Nippon Chemiphar Co., Ltd., H2 2016 92
Dyslipidemia - Pipeline by Omeros Corporation, H2 2016 93
Dyslipidemia - Pipeline by Pfizer Inc., H2 2016 94
Dyslipidemia - Pipeline by Pharmena SA, H2 2016 95
Dyslipidemia - Pipeline by Protalix BioTherapeutics, Inc., H2 2016 96
Dyslipidemia - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 97
Dyslipidemia - Pipeline by Sancilio & Company, Inc., H2 2016 98
Dyslipidemia - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 99
Dyslipidemia - Pipeline by Thetis Pharmaceuticals LLC, H2 2016 100
Dyslipidemia - Pipeline by Torrent Pharmaceuticals Limited, H2 2016 101
Dyslipidemia - Pipeline by Yuhan Corporation, H2 2016 102
Dyslipidemia - Pipeline by Zydus Cadila Healthcare Limited, H2 2016 103
Assessment by Monotherapy Products, H2 2016 104
Assessment by Combination Products, H2 2016 105
Number of Products by Stage and Target, H2 2016 107
Number of Products by Stage and Mechanism of Action, H2 2016 112
Number of Products by Stage and Route of Administration, H2 2016 118
Number of Products by Stage and Molecule Type, H2 2016 120
Dyslipidemia - Dormant Projects, H2 2016 303
Dyslipidemia - Dormant Projects (Contd..1), H2 2016 304
Dyslipidemia - Dormant Projects (Contd..2), H2 2016 305
Dyslipidemia - Dormant Projects (Contd..3), H2 2016 306
Dyslipidemia - Dormant Projects (Contd..4), H2 2016 307
Dyslipidemia - Dormant Projects (Contd..5), H2 2016 308
Dyslipidemia - Dormant Projects (Contd..6), H2 2016 309
Dyslipidemia - Dormant Projects (Contd..7), H2 2016 310
Dyslipidemia - Dormant Projects (Contd..8), H2 2016 311
Dyslipidemia - Dormant Projects (Contd..9), H2 2016 312
Dyslipidemia - Dormant Projects (Contd..10), H2 2016 313
Dyslipidemia - Dormant Projects (Contd..11), H2 2016 314
Dyslipidemia - Dormant Projects (Contd..12), H2 2016 315
Dyslipidemia - Dormant Projects (Contd..13), H2 2016 316
Dyslipidemia - Dormant Projects (Contd..14), H2 2016 317
Dyslipidemia - Dormant Projects (Contd..15), H2 2016 318
Dyslipidemia - Dormant Projects (Contd..16), H2 2016 319
Dyslipidemia - Discontinued Products, H2 2016 320
Dyslipidemia - Discontinued Products (Contd..1), H2 2016 321
Dyslipidemia - Discontinued Products (Contd..2), H2 2016 322
Dyslipidemia - Discontinued Products (Contd..3), H2 2016 323
Dyslipidemia - Discontinued Products (Contd..4), H2 2016 324
Dyslipidemia - Discontinued Products (Contd..5), H2 2016 325


List of Figures
Number of Products under Development for Dyslipidemia, H2 2016 22
Number of Products under Development for Dyslipidemia - Comparative Analysis, H2 2016 23
Number of Products under Development by Companies, H2 2016 24
Number of Products under Investigation by Universities/Institutes, H2 2016 29
Comparative Analysis by Late Stage Development, H2 2016 30
Comparative Analysis by Clinical Stage Development, H2 2016 31
Comparative Analysis by Early Stage Products, H2 2016 32
Assessment by Monotherapy Products, H2 2016 104
Assessment by Combination Products, H2 2016 105
Number of Products by Top 10 Targets, H2 2016 106
Number of Products by Stage and Top 10 Targets, H2 2016 106
Number of Products by Top 10 Mechanism of Actions, H2 2016 111
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 111
Number of Products by Routes of Administration, H2 2016 117
Number of Products by Stage and Routes of Administration, H2 2016 117
Number of Products by Molecule Types, H2 2016 119
Number of Products by Stage and Molecule Types, H2 2016 119
  • Global Infertility Treatment Market Analysis By Procedure (ART, Artificial Insemination, Fertility Surgery, Fertility Drugs, Others), Establishment (Fertility Clinics, Hospitals, Research Banks), By Region, By Country (2012-2022)
    Published: 12-Dec-2017        Price: US 2400 Onwards        Pages: 224
    Executive Summary A comprehensive research report published in December 2017, through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global  Infertility Treatment Market By Procedure (Assisted Reproductive Technique, Artificial Insemination, Fertility Surgery, Fertility Drugs, Other Procedures), By ART Type (IVF, ICSI, Other Procedure), Analysis By Patient Type ......
  • Global Gout Therapeutics Market Size, Status and Forecast 2022
    Published: 11-Dec-2017        Price: US 3300 Onwards        Pages: 113
    This report studies the global Gout Therapeutics market, analyzes and researches the Gout Therapeutics development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like - AstraZeneca - Takeda Pharmaceuticals - Horizon Pharma - Merck - Novartis - Sanofi - GlaxoSmithKline - Eli Lilly - Boehringer Ingelheim - Novo Nordisk - LG Life Sc......
  • Global Musculoskeletal Disorders Therapeutics Market Size, Status and Forecast 2022
    Published: 08-Dec-2017        Price: US 3300 Onwards        Pages: 107
    This report studies the global Musculoskeletal Disorders Therapeutics market, analyzes and researches the Musculoskeletal Disorders Therapeutics development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like - Pfizer - AbbVie - Johnson & Johnson - Sanofi - Merck - Novartis - Eli Lilly - AstraZeneca - Boehringer Ingelheim - F. Hoffmann-......
  • Global and Regional Varicose Vein Treatment Market Research Report 2017
    Published: 08-Dec-2017        Price: US 3500 Onwards        Pages: 130
    Summary There are several treatment options for Varicose Veins, wearing support stockings, Varicose Vein Treatment Devices; endogenous laser treatment, radiofrequency occlusion, surgery, and lasers and intense pulsed light. Mentioning medical devices for treating Varicose Veins, there is mainly Laser devices, Trivex and RFITT system. Market Segment as follows: By Region - Asia-Pacific - North America - Europe - South Americ......
  • Global Venous Thromboembolism Therapeutics Market Size, Status and Forecast 2022
    Published: 06-Dec-2017        Price: US 3300 Onwards        Pages: 101
    This report studies the global Venous Thromboembolism Therapeutics market, analyzes and researches the Venous Thromboembolism Therapeutics development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like - Johnson & Johnson - Sanofi - Boehringer Ingelheim - Daiichi Sankyo - Bristol-Myers Squibb (BMS) - Bayer HealthCare - Pfizer - Leo Pharma - P......
  • China Substance Abuse Treatment Market Research Report 2017
    Published: 05-Dec-2017        Price: US 3400 Onwards        Pages: 99
    The global Substance Abuse Treatment market is valued at XX million USD in 2016 and is expected to reach XX million USD by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. China plays an important role in global market, with market size of xx million USD in 2016 and will be xx million USD in 2022, with a CAGR of xx%. This report studies the Substance Abuse Treatment development status and future trend in China, focuses on top players in China, also s......
  • United States Brachytherapy Afterloaders, Brachytherapy Seeds Market Report 2017
    Published: 27-Nov-2017        Price: US 3800 Onwards        Pages: 100
    In this report, the United States Brachytherapy Afterloaders, Brachytherapy Seeds market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), ......
  • Global Substance Abuse Treatment Market Professional Survey Report 2017
    Published: 24-Nov-2017        Price: US 3500 Onwards        Pages: 108
    This report studies Substance Abuse Treatment in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering - Alkermes - Allergan - GSK - Pfizer - Accord Healthc......
  • Global Neuromodulation Market Size, Status and Forecast 2022
    Published: 24-Nov-2017        Price: US 3300 Onwards        Pages: 97
    This report studies the global Neuromodulation market, analyzes and researches the Neuromodulation development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like - Medtronic, Inc. (U.S.) - Boston Scientific Corporation (U.S.) - St. Jude Medical, Inc. (U.S.) - Synapse Biomedical, Inc. (U.S.) - Nevro Corporation (U.S.) - Neurosigma, Inc. (U.S.) - Neuropace,......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs